Treatment of older patients with multiple sclerosis: Results of an International Delphi Survey
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F23%3A10471038" target="_blank" >RIV/00669806:_____/23:10471038 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11140/23:10471038
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=W10rO9mgxO" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=W10rO9mgxO</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1177/20552173231198588" target="_blank" >10.1177/20552173231198588</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Treatment of older patients with multiple sclerosis: Results of an International Delphi Survey
Popis výsledku v původním jazyce
BackgroundPeople over age 50-55 have historically been excluded from randomized clinical trials for multiple sclerosis (MS). However, more than half of those living with an MS diagnosis are over 55.ObjectiveExplore the unique considerations of treating older people with MS (PwMS) using an iterative and structured Delphi-based assessment to gather expert opinions.MethodsEight MS neurologists with an interest in older PwMS developed a 2-round survey. Survey respondents were qualified neurologists with >= 3 years' experience, personally responsible for treatment decisions, and treating >= 20 patients per month, of whom >= 10% were >= 50 years old. Consensus was defined as >= 75% agreement on questions with categorical responses or as a mean score >= 4 on questions with numerical responses.ResultsIn Survey 1, 224 neurologists responded; 180 of these completed Survey 2. Limited consensus was reached with varying levels of agreement on several topics including identification and assessment of older patients; factors relating to treatment decisions including immunosenescence and comorbidities; considerations for high-efficacy treatments; de-escalation or discontinuation of treatment; effects of COVID-19; and unmet needs for treating this population.ConclusionThe results of this Delphi process highlight the need for targeted studies to create guidance for the care of older PwMS.
Název v anglickém jazyce
Treatment of older patients with multiple sclerosis: Results of an International Delphi Survey
Popis výsledku anglicky
BackgroundPeople over age 50-55 have historically been excluded from randomized clinical trials for multiple sclerosis (MS). However, more than half of those living with an MS diagnosis are over 55.ObjectiveExplore the unique considerations of treating older people with MS (PwMS) using an iterative and structured Delphi-based assessment to gather expert opinions.MethodsEight MS neurologists with an interest in older PwMS developed a 2-round survey. Survey respondents were qualified neurologists with >= 3 years' experience, personally responsible for treatment decisions, and treating >= 20 patients per month, of whom >= 10% were >= 50 years old. Consensus was defined as >= 75% agreement on questions with categorical responses or as a mean score >= 4 on questions with numerical responses.ResultsIn Survey 1, 224 neurologists responded; 180 of these completed Survey 2. Limited consensus was reached with varying levels of agreement on several topics including identification and assessment of older patients; factors relating to treatment decisions including immunosenescence and comorbidities; considerations for high-efficacy treatments; de-escalation or discontinuation of treatment; effects of COVID-19; and unmet needs for treating this population.ConclusionThe results of this Delphi process highlight the need for targeted studies to create guidance for the care of older PwMS.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30103 - Neurosciences (including psychophysiology)
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2023
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Multiple Sclerosis Journal - Experimental, Translational and Clinical
ISSN
2055-2173
e-ISSN
2055-2173
Svazek periodika
9
Číslo periodika v rámci svazku
3
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
11
Strana od-do
20552173231198588
Kód UT WoS článku
001093076700001
EID výsledku v databázi Scopus
2-s2.0-85176422596